Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | completed | Phase 1 | 15 | Clemens TempferOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03509636 | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | completed | Phase 1 | 113 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02324439 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | completed | Phase 1 | 15 | Southern Illinois UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | unknown | Phase 1 | 80 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05270720 | Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | unknown | Phase 1 | 9 | West China Second University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | terminated | Phase 1 | 11 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05211557 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | unknown | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT02303912 | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer(ProGem2) | completed | Phase 1 | 25 | Imperial College Healthcare NHS TrustOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02269293 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03507543 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03213964 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | completed | Phase 1 | 10 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | completed | Phase 1 | 25 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2022source: clinicaltrials